Literature DB >> 12360492

Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.

Ali Canbay1, Hajime Higuchi, Steven F Bronk, Makiko Taniai, Tom J Sebo, Gregory J Gores.   

Abstract

BACKGROUND & AIMS: Hepatocyte apoptosis and fibrosis are both features of liver injury. However, the potential mechanistic link between these 2 processes remains obscure. Our aim was to ascertain if Fas-mediated hepatocyte apoptosis promotes liver fibrogenesis during extrahepatic cholestasis.
METHODS: Wild-type and Fas-deficient lymphoproliferation (lpr) mice underwent bile duct ligation. Liver injury was assessed by quantitating hepatocyte apoptosis with the terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay and determining serum ALT values. mRNA expression was quantitated using real-time polymerase chain reaction technology. Liver fibrosis was assessed by digital image analysis of Sirius red-stained sections.
RESULTS: In 3-day bile duct ligated (BDL) animals, TUNEL-positive hepatocytes and serum ALT values were reduced in lpr versus wild-type animals. Likewise, hepatic mRNA transcripts for alpha-smooth muscle actin and platelet-derived growth factor receptor-beta (initiation phase of stellate cell activation) and transforming growth factor beta1 mRNA, collagen 1alpha, and tissue inhibitor of matrix metalloproteinases (perpetuation phase of stellate cell activation) were also reduced in 3-day BDL wild-type mice compared with lpr mice. Finally, in 3-week BDL mice, immunoreactivity for alpha-smooth muscle actin and Sirius red staining for collagen were significantly less in lpr compared with wild-type animals.
CONCLUSION: Fas-mediated hepatocyte injury is mechanistically linked to liver fibrogenesis. These observations suggest that inhibition of Fas-mediated apoptosis may be a therapeutic antifibrogenic strategy in cholestatic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12360492     DOI: 10.1053/gast.2002.35953

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  87 in total

1.  Toll-like receptors 2 and 4 are differentially involved in Fas dependent apoptosis in Peyer's patch and the liver at an early stage after bile duct ligation in mice.

Authors:  A Ogawa; T Tagawa; H Nishimura; T Yajima; T Abe; T Arai; M Taniguchi; K Takeda; S Akira; Y Nimura; Y Yoshikai
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH.

Authors:  Xiaoya Li; Jing Wang; Xue Gong; Meiling Zhang; Shuangshuang Kang; Bing Shu; Zuzhuang Wei; Zhi-Shu Huang; Ding Li
Journal:  Nucleic Acids Res       Date:  2020-09-04       Impact factor: 16.971

Review 3.  Apoptosis: a mechanism of acute and chronic liver injury.

Authors:  M E Guicciardi; G J Gores
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  Pericytes in the Liver.

Authors:  Enis Kostallari; Vijay H Shah
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

6.  Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Authors:  Alisan Kahraman; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Fernando J Barreyro; Maria E Guicciardi; Yuko Akazawa; Karen Braley; Ruth W Craig; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

7.  Hyperoxia accelerates progression of hepatic fibrosis by up-regulation of transforming growth factor-β expression.

Authors:  Sang Hwa Lee; Sung-Im Do; Hyun-Soo Kim
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis.

Authors:  Yury Popov; Deanna Y Sverdlov; K Ramakrishnan Bhaskar; Anisha K Sharma; Gunda Millonig; Eleonora Patsenker; Stephan Krahenbuhl; Lukas Krahenbuhl; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-01-07       Impact factor: 4.052

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

10.  Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.

Authors:  M Marzioni; G Alpini; S Saccomanno; C Candelaresi; J Venter; C Rychlicki; G Fava; H Francis; L Trozzi; A Benedetti
Journal:  Gut       Date:  2008-10-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.